Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 850
Rating:

Prof Robin Foa - University of Rome, Rome, Italy

Prof Robin Foa speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the combination of dasatinib and blinatumomab for the front-line treatment of adult Ph-positive acute lymphoblastic leukaemia (ALL).

He explains that the addition of blinatumomab to dasatinib showed promising results with a rate of complete molecular response of around 65% compared with 25% for dasatinib alone.

Prof Foa highlights that this shows you can get a very high rate of complete molecular response without chemotherapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation